^
    Apply
    A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8) (NCT05211895)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    02/18/2022
    Primary completion :
    06/27/2028
    Completion :
    08/30/2030
    EGFR • PD-L1
    |
    EGFR wild-type • ALK wild-type
    |
    Imfinzi (durvalumab) • domvanalimab (AB154)
    Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (NCT04736173)
    Phase 3
    Arcus Biosciences, Inc.
    Active, not recruiting
    Last update posted :
    06/06/2024
    Initiation :
    02/08/2021
    Primary completion :
    08/31/2024
    Completion :
    07/01/2027
    PD-L1
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154) • mitazalimab (ADC-1013)
    A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric) (NCT05329766)
    Phase 2
    Arcus Biosciences, Inc.
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    06/10/2022
    Primary completion :
    09/01/2026
    Completion :
    06/01/2027
    PD-L1
    |
    PD-L1 expression
    |
    5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154) • quemliclustat (AB680)
    Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) (NCT05633667)
    Phase 2
    Gilead Sciences
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    03/16/2023
    Primary completion :
    01/01/2027
    Completion :
    01/01/2027
    EGFR • PD-L1 • ALK
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • Trodelvy (sacituzumab govitecan-hziy) • domvanalimab (AB154) • etrumadenant (AB928)
    Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7) (NCT04262856)
    Phase 2
    Arcus Biosciences, Inc.
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    05/28/2020
    Primary completion :
    02/01/2025
    Completion :
    02/01/2025
    PD-L1
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928) • mitazalimab (ADC-1013)
    Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma (NCT05130177)
    Phase 2
    Diwakar Davar
    Recruiting
    Last update posted :
    05/06/2024
    Initiation :
    03/16/2022
    Primary completion :
    01/01/2027
    Completion :
    01/01/2030
    BRAF • CTLA4
    |
    BRAF mutation
    |
    Yutuo (zimberelimab) • domvanalimab (AB154)
    Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121) (NCT05502237)
    Phase 3
    Gilead Sciences
    Recruiting
    Last update posted :
    05/01/2024
    Initiation :
    10/12/2022
    Primary completion :
    09/01/2027
    Completion :
    09/01/2027
    EGFR • BRAF • ALK • RET • NTRK
    |
    BRAF mutation • ALK mutation • RET mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer (NCT04791839)
    Phase 2
    Washington University School of Medicine
    Active, not recruiting
    Last update posted :
    04/09/2024
    Initiation :
    08/04/2021
    Primary completion :
    01/31/2025
    Completion :
    04/30/2029
    PD-L1
    |
    PD-L1 expression
    |
    Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928)
    Peri-operative Zimberelimab (Anti-PD-1) vs Zimberelimab in Combination With Domvanalimab (Anti-TIGIT) in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric and Gastro-oesophageal Junctional Adenocarcinoma (ZODIAC) (NCT06250036)
    Phase 2
    Royal Marsden NHS Foundation Trust
    Not yet recruiting
    Last update posted :
    02/08/2024
    Initiation :
    04/01/2024
    Primary completion :
    09/01/2026
    Completion :
    09/01/2031
    MSI
    |
    MSI-H/dMMR
    |
    Yutuo (zimberelimab) • domvanalimab (AB154)